This initiative is intended to stimulate the commercial development of novel radioligands for positron emission tomography (PET) and single photon emission computed tomography (SPECT) imaging in human brain, and to incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.
The NIH institutes listed in this PA are specifically interested in the development of radioligands for molecular targets (e.g., receptors, cell adhesion molecules, intracellular messengers, and disease related proteins) that are of broad interest to the scientific community. These radiotracers will be used for neuroimaging as well as potential biological markers and surrogate endpoints for translational and clinical research, drug discovery and development, and clinical trials. Also appropriate for this PA are applications proposing research and development of new technologies for radiotracer development.
Who can apply:
Private Institutions Of Higher Education
Small Business (Less Than 500 Employees
Eligible functional categories:
Mental Health Research Grants
If you have problems accessing the full announcement, please contact:
NIH OER Webmaster